Chronic urticaria associated with autoreactivity to progesterone

Journal of the European Academy of Dermatology and Venereology

Volumn 9, Issue 2, 1997, Pages 173-176

  De Sousa Pinto, J M ^a,b   Campos, Luis B ^c   De Ascensão, A Cabral ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b Clin Univ Dermatologia V   (Portugal)

^c H de São Francisco Xavier ^*  (Portugal)

Author keywords

Autoimmunity; Chronic urticaria; Oophorectomy; Progesterone; Thalidomide

Indexed keywords

CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; THALIDOMIDE;

ADULT; ARTICLE; AUTOIMMUNITY; CASE REPORT; CHRONIC URTICARIA; DERMATITIS; DIAGNOSIS; DISEASE ASSOCIATION; DRUG THERAPY; ETIOLOGY; FEMALE; HUMAN; HUMAN TISSUE; INTRADERMAL DRUG ADMINISTRATION; LUTEAL PHASE; MENSTRUAL CYCLE; OVARIECTOMY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SKIN BIOPSY;

EID: 0030757746     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(97)00061-5     Document Type: Article

References (40)

1. Hart R. Autoimmune progesterone dermatitis. Arch Dermatol 1977;113:426-430.
2. Meggs WI, Pescovitz OH, Metcalfe D, et al. Progesterone sensitivity as a cause of recurrent anaphylaxis. N Engl J Med 1984;311:1236-1238.
3. Shelley WB, Preucel RW, Spoont SS. Autoimmune progesterone dermatitis. Cure by oophorectomy. J Am Med Assoc 1964;190:35-38.
4. Jones WN, Gordon VH. Autoimmune progesterone eczema. Arch Dermatol 1969;99:57-59.
5. Torras H, Ferrando J, Mallolas J. Dermatitis postovulation (Dermatitis por progesterona) Med Cut ILA 1980; VIII: 15-22.
6. Berger H. Ulcerative stomatitis caused by endogenous progesterone. Ann Intern Med 1955;42:205-208.
7. Cheesman KL, Gaynor LV, Chatterton Jr RT, et al. Identification of a 17-hydroxyprogesterone - binding immunoglobulin in the serum of a woman with periodic rashes. J Clin Endocrinol Metab 1982;55:597-599.
8. Pinto JS, Sobrinho L, da Silva MB et al. Erythema multiforme associated with autoreactivity to 17-α-hydroxyprogesterone. Dermatologica 1990;180:146-150.
9. Friedman-Birnbaum R, Gilhar A, Haim S. Sensitivity to endogenous progesterone. Report of a case. Dermatologica 1981;162:391-394.
10. Stephens CJM, Wojnarowska FT, Wilkinson JD. Autoimmune progesterone dermatitis responding to Tamoxifen. Br J Dermatol 1989;121:135-137.
11. Bierman SM. Autoimmune progesterone dermatitis of pregnancy. Arch Dermatol 1973;107:896-901.
12. Farah FS, Shbaklu Z. Autoimmune progesterone urticaria. J Allergy Clin Immunol 1971;48:257-261.
13. Huetz F, Jacquemart F, Rossi CP, Varela F, Coutinho A. Autoimmunity. The moving boundaries between physiology and pathology. J Autoimmun 1988;1:507-518.
14. Herzberg AJ, Strohmeyer CR, Cirillo-Hyland VA. Autoimmune progesterone dermatitis, J Am Acad Dermatol 1995;32:335-338.
15. Miura T, Matsuda M, Yanbe H, et al. Two cases of autoimmune progesterone dermatitis. Immunohistochemical and serological studies. Acta Derm Venereol (Stockh) 1989;69:308-310.
16. Linse R, Hadlich J. Autoimmune progesterondermatose. Dermatol Monatsschr 1978;164:656-661.
17. Heubaum F, Kostler E, Seebacher C. Die autoimmune progesteron dermatose eine menstruations und schwangerschaftsdermatose. Dermatol Monatsschr 1981;167:753-759.
18. Baló-Banga JM, Pfeiffer I. Chromatin activation of blood lymphocytes detected by polarization microscopy and cytophotometry. Anal Quant Cytol Hist 1986;8:63-70.
19. Knop J, Bonsmann G, Happle R et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythaematosus. Br J Dermatol 1983;108:461-466.
20. Samsoen M, Grosshans E, Basset A. La thalidomide dans le traitment du lupus erythemateux chronique. Ann Dermatol Venereol 1980;107:515-523.
21. Bessis D, Guillot B, Monpoint S, et al. Thalidomide for systemic lupus erythematosus. Lancet 1992;339:549-550.
22. Hamza M, Chaffai M, Ben Hayed H. Le traitment de la maladie de Behçet par la thalidomide. Nouv Press Méd 1982;11:1080-1081.
23. Pinto JS, Freitas JP, Jorge JP, et al. Follow-up of 60 cases of Behçet's Syndrome. In O'Duffy JD, Kokmen E Eds. Behçet's disease. Basic and Clinical Aspects. Marcel Dekker Inc. 1991; 313-319.
24. Grinspan D. Significant response of oral aphtosis to thalidomide treatment. J Am Acad Dermatol 1985;12:85-90.
25. Revuz J, Guilhaume J, Janvier M et al. Crossover study of thalidomide vs. placebo in severe recurrent aphtous stomatitis. Arch Dermatol 1990;126:923-927.
26. Rustin MHA, Gilkes JJH, Robinson TWE. Pyoderma gangrenosum associated with Behçet's disease: Treatment with thalidomide. J Am Acad Dermatol 1990;23:941-944.
27. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-306.
28. Lim SH, McWhannell A, Vora AJ et al. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet 1988;i:1-17.
29. Vogelsang GB, Hess AD, Friedman KJ, et al. Therapy of chonic graft-versus-host disease in a rat model. Blood 1989;74:507-511.
30. Vogelsang GB, Hess AD, Santos GW. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant 1988;3:393-398.
31. Shannon EJ, Miranda RO, Morales MJ, et al. Inhibition of de novo antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 1981;13:553-562.
32. Gad SM, Shannon EJ, Krotski WA, et al. Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 1985;56:35-39.
33. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991;173:699-703.
34. Faure M, Thivolet J, Gancherand M. Inhibition of PMN leucocyte chemotaxis by thalidomide. Arch Dermatol Res 1980;269:275-280.
35. Barnhill RL, Doll NJ, Millikan LE, et al. Studies on the antiinflamatory properties of thalidomide: effects on polymorphonuclear leuckocytes and monocytes. J Am Acad Dermatol 1984;11:814-819.
36. Bore PJ, Scothorne RJ. Effect of thalidomide on survival of skin homografts in rabbits. Lancet 1966;ii:1240-1241.
37. Keenan RJ, Eiras G, Burckart GJ, et al. Immunosupressive properties of thalidomide. Transplantation 1991;52:908-910.
38. Lindahl-Kiessling K, Böök JA. Effects of thalidomide on human leucocyte cultures. Lancet 1963;ii:405.
39. Arala-Chaves M, Vilanova M, Ribeiro A, et al. I. Immunostimulatory effect of thalidomide in normal C 57 BL/6 mice is compatible with stimulation of a highly connected central immune system. Scand J Immunol 1994;40:535-542.
40. Vilanova M, Ribeiro A, Carneiro J, et al. II. The effects of thalidomide treatment on autoimmune-prone NZB and MRL mice are consistent with stimulation of the central immune system. Scand J Immunol 1994;40:543-548.